Skip to contentP
Phathom Pharmaceuticals, Inc.
P
PHATPhathom Pharmaceuticals, Inc. Q1 2026 · 10-Q
Revenue$58.30M$58.30M+104.4% vs Q1 2025 Net Income-$30.37M-$30.37MN/M vs Q1 2025 EPS Diluted-$0.37-$0.37N/M vs Q1 2025 Gross Profit$46,305,000+86.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Phathom Pharmaceuticals, Inc. · CIK 1783183 · Engraved from SEC EDGAR
Operating Cash Flow-$15,647,000N/M Free Cash Flowderived-$15,708,000N/M Margins · derivedGross margin79.4%−7.5 pt vs Q1 2025
Operating margin-26.5%+250.0 pt vs Q1 2025
Net margin-52.1%+278.6 pt vs Q1 2025
ended Mar 31, 2026 · filed Apr 30, 2026 · 30 d after period end